Researchers find new path to promising Parkinson's treatment

September 19, 2017 by Adam Jones, University of Alabama in Tuscaloosa
Ball-and-stick model of the dopamine molecule, a neurotransmitter that affects the brain's reward and pleasure centers. Credit: Jynto/Wikipedia

Three researchers at The University of Alabama are part of work that is leading to a new direction for drug discovery in the quest to treat Parkinson's disease.

Findings from the study are published today in the journal Nature Neuroscience, with the UA researchers among the co-authors.

"This provides real evidence for a long-sought mechanism, and, simultaneously, it provides a good rationale for a different path for ," said Dr. Guy Caldwell, University Distinguished Research Professor in . "This path and these ideas have been out there. This paper really brings it together and supports the evidence for those ideas."

Guy Caldwell is a co-author on the paper that includes Dr. Kim Caldwell, professor of biological sciences at UA, and Hanna Kim, a doctoral student in the Caldwell lab who is the primary UA contributor.

Parkinson's disease, a neurodegenerative disorder, is estimated to afflict between seven and 10 million people worldwide with approximately 60,000 Americans diagnosed each year. Current therapies include treating the symptoms of the disease such as tremor and involuntary shakes, but there is no cure or treatment to halt the disease's progression.

Hallmarks of Parkinson's disease are the loss of cells, or neurons, that send information to other parts of the brain, specifically neurons that produce a type of information-carrying chemical known as , along with the accumulation, or clumping, of proteins in the neurons.

To work, proteins must fold properly within cells. When extra copies or mutations of the protein alpha-synuclein are present in , a series of misfoldings can occur, leading to aggregation of proteins. Such protein aggregation within the brain's dopamine-producing neurons can lead to their malfunction or cell death, triggering the symptoms of Parkinson's.

When a Parkinson's patient is exhibiting symptoms of the disease, they have likely lost up to 80 percent of the dopamine neurons in their bodies, Guy Caldwell said.

The mystery in Parkinson's research is why are vulnerable to alpha-synuclein clumping, he said. The answer, according to the latest findings, is dopamine. Dopamine has the ability to bind alpha-synuclein, making it more toxic, according to the study.

"This seems to be possibly a real root mechanism of pathogenesis that is a direct interaction between dopamine and the pathogenic protein alpha-synuclein," he said. "If we can find a way to block the interaction of dopamine and alpha-synuclein directly, then that would be therapeutic."

The idea that dopamine causes the clumping has been shown in test tubes using chemicals, but the latest work proved its consequences in animal models.

At UA, researchers in the Caldwell lab work with tiny roundworms known as C. elegans, which shares roughly half its genes with humans. Its basic features allow inexpensive and rapid testing for a range or neurological diseases, and UA researchers can induce Parkinson's-like effects in the worm for testing.

Hanna Kim was able to demonstrate dopamine's effects on alpha-synuclein within the worm, and researchers at the University of Pennsylvania, the lead institution on the study, also showed the mechanism in mice.  An impetus for this work came from previously published UA-based research from the Caldwell lab that showed excess dopamine production was toxic in the worm model.

The group has already moved onto the next step of finding ways to block the process, and Kim has shown that removing spots of interaction, or sequences of amino acids in a protein, between dopamine and alpha-synuclein enhances the survival of , halting the progression of the disease state.

"It was a nice confirmation that in a living animal model system, preventing the interaction between dopamine and could alleviate the neurotoxicity that occurred," Guy Caldwell said.

The paper "Dopamine induces soluble α-synuclein oligomers and nigrostriatal degeneration" is published online today and will appear in an upcoming issue of Nature Neuroscience. The work was supported by the National Institutes of Health.

Explore further: Tug of war between Parkinson's protein and growth factor

More information: Danielle E Mor et al. Dopamine induces soluble α-synuclein oligomers and nigrostriatal degeneration, Nature Neuroscience (2017). DOI: 10.1038/nn.4641

Related Stories

Tug of war between Parkinson's protein and growth factor

September 18, 2017
Alpha-synuclein, a sticky and sometimes toxic protein involved in Parkinson's disease (PD), blocks signals from an important brain growth factor, Emory researchers have discovered.

A new insight into Parkinson's disease protein

July 28, 2017
Abnormal clumps of certain proteins in the brain are a prominent feature of Parkinson's and other neurodegenerative diseases, but the role those same proteins might play in the normal brain has been unknown.

Parkinson's is partly an autoimmune disease, study finds

June 21, 2017
Researchers have found the first direct evidence that autoimmunity—in which the immune system attacks the body's own tissues—plays a role in Parkinson's disease, the neurodegenerative movement disorder. The findings raise ...

Lipid deficiency linked to neuron degeneration

September 9, 2014
A type of lipid that naturally declines in the aging brain impacts – within laboratory models used to study Parkinson's disease – a protein associated with the disease, according to a study co-authored by University of ...

Treating with antioxidants early in Parkinson's disease process may halt degeneration and improve neuronal function

September 7, 2017
Northwestern Medicine scientists have identified a toxic cascade that leads to neuronal degeneration in patients with Parkinson's disease (PD) and figured out how to interrupt it, reports a study to be published September ...

Researchers increase understanding of gene's potentially protective role in Parkinson's

February 7, 2012
Treatments for Parkinson's disease, estimated to affect 1 million Americans, have yet to prove effective in slowing the progression of the debilitating disease.

Recommended for you

New evidence sheds light on how Parkinson's disease may happen

June 14, 2018
Researchers at Baylor College of Medicine and Texas Children's Hospital have identified unexpected new key players in the development of an early onset form of Parkinson's disease called Parkinsonism. These key players are ...

Scientists unravel molecular mechanisms of Parkinson's disease

June 12, 2018
Detailed brain cell analysis has helped researchers uncover new mechanisms thought to underlie Parkinson's disease.

First photoactive drug to fight Parkinson's disease

June 8, 2018
An international team has designed the first potentially therapeutic photoactive drug, MRS7145, to fight Parkinson's disease, according to the new article in Journal of Controlled Release.

Researchers address sleep problems in Parkinson's disease

June 7, 2018
A team of researchers at VIB and KU Leuven has uncovered why people with a hereditary form of Parkinson's disease suffer from sleep disturbances. The molecular mechanisms uncovered in fruit flies and human stem cells also ...

Drugs that suppress immune system may protect against Parkinson's

May 31, 2018
People who take drugs that suppress the immune system are less likely to develop Parkinson's disease, according to a study from Washington University School of Medicine in St. Louis.

Early synaptic dysfunction found in Parkinson's Disease

May 24, 2018
Northwestern Medicine scientists identified a cellular mechanism that leads to neurodegeneration in patients with Parkinson's disease, according to a study published in Proceedings of the National Academy of Sciences.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.